LUMO Stock Overview
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases.
Lumos Pharma Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$7.71|
|52 Week High||US$11.52|
|52 Week Low||US$6.15|
|1 Month Change||-1.78%|
|3 Month Change||-17.98%|
|1 Year Change||-22.90%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-11.99%|
Recent News & Updates
Here's Why We're Not Too Worried About Lumos Pharma's (NASDAQ:LUMO) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
|LUMO||US Biotechs||US Market|
Return vs Industry: LUMO exceeded the US Biotechs industry which returned -26.1% over the past year.
Return vs Market: LUMO underperformed the US Market which returned -20.4% over the past year.
|LUMO Average Weekly Movement||7.4%|
|Biotechs Industry Average Movement||13.1%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: LUMO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: LUMO's weekly volatility (7%) has been stable over the past year.
About the Company
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
Lumos Pharma Fundamentals Summary
|LUMO fundamental statistics|
Is LUMO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|LUMO income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-3.53|
|Net Profit Margin||-8,656.60%|
How did LUMO perform over the long term?See historical performance and comparison
Is LUMO undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for LUMO?
Other financial metrics that can be useful for relative valuation.
|What is LUMO's n/a Ratio?|
Price to Book Ratio vs Peers
How does LUMO's PB Ratio compare to its peers?
|LUMO PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
DBTX Decibel Therapeutics
EFTR eFFECTOR Therapeutics
MTEM Molecular Templates
LUMO Lumos Pharma
Price-To-Book vs Peers: LUMO is good value based on its Price-To-Book Ratio (0.8x) compared to the peer average (1.5x).
Price to Earnings Ratio vs Industry
How does LUMO's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Book vs Industry: LUMO is good value based on its Price-To-Book Ratio (0.8x) compared to the US Biotechs industry average (1.6x)
Price to Book Ratio vs Fair Ratio
What is LUMO's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||0.8x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate LUMO's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of LUMO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate LUMO's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate LUMO's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate LUMO's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Lumos Pharma forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LUMO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: LUMO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: LUMO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: LUMO's revenue (86.4% per year) is forecast to grow faster than the US market (8.3% per year).
High Growth Revenue: LUMO's revenue (86.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if LUMO's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Lumos Pharma performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: LUMO is currently unprofitable.
Growing Profit Margin: LUMO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: LUMO is unprofitable, and losses have increased over the past 5 years at a rate of 31% per year.
Accelerating Growth: Unable to compare LUMO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LUMO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: LUMO has a negative Return on Equity (-36.08%), as it is currently unprofitable.
Discover strong past performing companies
How is Lumos Pharma's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: LUMO's short term assets ($92.6M) exceed its short term liabilities ($5.2M).
Long Term Liabilities: LUMO's short term assets ($92.6M) exceed its long term liabilities ($6.1M).
Debt to Equity History and Analysis
Debt Level: LUMO is debt free.
Reducing Debt: LUMO had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: LUMO has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: LUMO has sufficient cash runway for 2.3 years if free cash flow continues to reduce at historical rates of 32% each year.
Discover healthy companies
What is Lumos Pharma current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate LUMO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate LUMO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if LUMO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if LUMO's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as LUMO has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Rick Hawkins (72 yo)
Mr. Richard J. Hawkins, also known as Rick, is the Founder of Lumos Pharma, Inc. and has been its Chairman of the Board since March 26, 2020, its Chief Executive Officer since January 2011 and served as it...
CEO Compensation Analysis
Compensation vs Market: Rick's total compensation ($USD1.35M) is above average for companies of similar size in the US market ($USD759.63K).
Compensation vs Earnings: Rick's compensation has been consistent with company performance over the past year.
Experienced Management: LUMO's management team is considered experienced (2.2 years average tenure).
Experienced Board: LUMO's board of directors are considered experienced (6.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Lumos Pharma, Inc.'s employee growth, exchange listings and data sources
- Name: Lumos Pharma, Inc.
- Ticker: LUMO
- Exchange: NasdaqGM
- Founded: NaN
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$64.527m
- Shares outstanding: 8.37m
- Website: https://www.lumos-pharma.com
Number of Employees
- Lumos Pharma, Inc.
- 4200 Marathon Boulevard
- Suite 200
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/29 00:00|
|End of Day Share Price||2022/06/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.